Ami Fadia

Douglas Tsao

Joon Lee

Ritu Baral

Yasmeen Rahimi

Yatin Suneja

François Brisebois

Joel Beatty

Kambiz Yazdi

Brian Skorney

David Hoang

Doug Tsao

Jay Olson

Laura Chico

Rudy Li

- Praxis Precision Medicines (PRAX) reported that its drug candidate, vormatrigine, achieved a **56% sustained overall seizure reduction rate** in the RADIAN study.  **[1689548_tx_381223_2]**  Additionally, **22% of patients saw 100% seizure reduction** in the last 28 days, with **14% being seizure-free over the entire eight-week treatment period**.  **[1689548_tx_381223_5]**  These results are considered "**best of disease**" and represent the "**largest effects ever seen**" at eight weeks compared to other drugs.  **[1689548_tx_381223_6]** 
- The company expects the ongoing Power One study to show **at or better than 56% seizure reduction**.  **[1689548_tx_381223_10]**  The larger Power Two study is starting in the last month of Q3 2025, with recruitment expected to take **10 to 12 months** and finalization late next year.  **[1689548_tx_381223_11]**  This study, using a higher 40mg dose, is anticipated to show an **even better response** and, combined with Power One, could enable regulatory submission (NDA) in the next **18 months or so**.  **[1689548_tx_381223_8]** **[1689548_tx_381223_11]** 
- While the RADIAN study had higher-than-expected discontinuation rates, these were attributed to patient counseling and site experience rather than treatment-emergent adverse events (TEAEs), which were significantly lower than other drugs.  **[1689548_tx_381223_8]** **[1689548_tx_381223_9]**  Power One is already showing much lower discontinuation rates.  **[1689548_tx_381223_9]** 
- Vormatrigine holds significant commercial potential, with a projected **$1.5 billion peak sale** in the refractory epilepsy market, and potentially over **$3 billion** with broader use, including replacing less effective current treatments like levetiracetam.  **[1689548_tx_381223_10]**

Praxis Precision Medicines Discusses Vormatrigine Clinical Data and Commercial Outlook